Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USP Final Formulary Guide Adds PPI Class, But Has Few Other Changes

Executive Summary

Proton pump inhibitors may be the only commercially significant group of drugs to gain "pharmacologic class" status in the revisions to U.S. Pharmacopeia's model guidelines for Medicare drug plans

You may also be interested in...



CMS Medicare Formulary Reviews Include 14 Checkpoints

The Centers for Medicare & Medicaid Services has a 14-point checklist it is using in the review of Medicare Part D drug formularies

CMS Medicare Formulary Reviews Include 14 Checkpoints

The Centers for Medicare & Medicaid Services has a 14-point checklist it is using in the review of Medicare Part D drug formularies

Medicare Formularies Should Contain “Majority” Of Drugs In Six Classes

Medicare drug plan formularies will be expected to cover the "majority" of products in six specific drug classes, the Centers for Medicare & Medicaid Services final formulary review guidelines state

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel